Kornimate/medical-research-clean huggingface dataset:
biomechanics responses to power and strength combined training

Conditions: Healthy

Summary: anterior cruciate ligament (acl) is the most frequently injured knee ligament during performance of recreational activities and sports. in the united states, the annual incidence is 68.6 per 100,000 people per year and in brazil, the estimation of acl reconstruction increases 64%. there are different biomechanical profiles of risk factors for an acl injury variable, the ligament dominance, the quadriceps dominance, the trunk dominance, and the leg dominance. thus, the purpose of this study is to investigate the biomechanics adaptations after power and strength combined training protocol in healthy individuals. a second aim is to determine the effect of the training on knee injury risk factors.

this is a parallel randomized clinical trial comparing the effect of combined training with power and strength exercises on lower extremity biomechanics in healthy individuals. the sample size was calculated with g\*power software using the anova: repeated measures, within-between interaction, 90% power, alpha 0.05, and 30% drop-out. data from the tuck jump test (knee flexion range) by makaruk (2014) were considered for this calculation with effect size 0.46. thus, a total of 32 individuals (16 per group) is required for this study. to ensure the proper simple size, after collecting the first five participants per group, the sample size will be checked again. the participants will be randomized in experimental and no intervention groups inside each risk profile group. randomization ratio will be 1:1 and interventions will last 10 weeks, with two weekly sessions for the exercise arms. the outcomes will include functional clinical tests, kinematic and kinetic variables during landing tasks, and strength of knee and hip muscles. the data analysis will be performed by intention to treat and per protocol. generalized estimating equations will be used to identify interaction effects of groups and time followed by bonferroni post-hoc. when effect are found, effect size will be estimated. missing data will be estimate by statistical analysis.

Eligibility criteria:
inclusion criteria: * male sex; * age between 18 and 30 years old; * who practice physical activity (except: strength and jump training) between 80 and 150 minute per week; * no previous muscle lower extremity injury at least 6 months prior to recruitment; * no previous ligament and tendon lower extremity injury or surgery; * no auditory, vestibular, visual or musculoskeletal injuries or disease that impairment the execution of assessments or training protocol; * no hypertension, cardiovascular or respiratory disease. exclusion criteria: * body mass index greater than 35 kg/m².

Keywords: adult anterior cruciate ligament injuries lower extremity
multidisciplinary intervention for mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: the purpose of this investigation is to conduct a series of case studies on the impact of a novel functional medicine approach to improving cognitive skills, brain structure, and daily functioning for participants with mild cognitive impairment (mci).

using a multiple baseline design across cases with start point randomization, the proposed study will examine the outcomes from a combination of optimized diet, exercise, nutritional supplements, and cognitive training across domains on standardized measures used to monitor treatment effectiveness for mild cognitive impairment (mci).

Eligibility criteria:
inclusion criteria: * age 50+ previously diagnosed with mci * living in the greater colorado springs area exclusion criteria: * no braces, metal implants, or claustrophobia that would contraindicate magnetic resonance imaging
investigational tms treatment for depression

Conditions: Depression; Treatment Resistant Depression

Summary: this study is aimed to help us learn about the effects of transcranial magnetic stimulation at the forehead versus the left side of the head for treatment of treatment resistant depression.

while transcranial magnetic stimulation (tms) to the left dorsolateral prefrontal cortex (dlpfc) is an fda approved treatment for depression, a growing and converging database suggests the medial prefrontal cortex (mpfc) may be even more critical to the neurobiology of depression and antidepressant treatment response. this study will compare the efficacy of high frequency transcranial madntic stimulation on these two sections of the brain.

Eligibility criteria:
inclusion criteria: * 21-70 years old * inadequate response to one current antidepressant medication * currently depressed exclusion criteria: * psychiatric comorbidities

Keywords: depression trd treatment-resistant depression tms
compact pneumatic compression device for patients with lymphedema

Conditions: Lymphedema of Limb

Summary: this is a pilot study for usability and efficacy, and as such it is designed for 15 participants. the primary objective of this study is to assess the usability of the monterey investigational system in the home setting. the primary objective of this study is to assess the usability of the monterey investigational system in the home setting over one week of daily use. usability will be determined using a 11 point likert scale where a score of 10 is considered very favorable and a score of 0 is very unfavorable.


Eligibility criteria:
inclusion criteria: * patients who are ≥ 18 years, mentally able to understand and follow the instructions of the study personnel. * a diagnosis of lower limb lymphedema. * able to provide written and informed consent. * patient can read and comprehend english. exclusion criteria: * subject undergoing cancer treatment. * subject has active lower limb wounds. * subject is pregnant or trying to become pregnant. * history of pulmonary edema or decompensated congestive heart failure. * subject has any condition in which increased venous and lymphatic return is undesirable. * subject has inbuilt electrical stimulator, e.g., cardiac pacemaker
functional improvement in patients with parkinson's disease after training in real or virtual environment

Conditions: Parkinson´s Disease

Summary: the objective of this work was to compare the effects of two balance training programs, one nintendo wii fit-based and the other traditionally-based without the use of a gaming system, on the balance, functionality and cognition of patients with parkinson´s disease. it was a prospective, single blinded, randomized clinical trial performed at brazil parkinson association and center of research of the courses of speech therapy, physical therapy and occupational therapy of são paulo university. 32 patients with parkinson´s disease on stages 1 and 2,5 of hoehn e yahr participated of this work. patients were randomized in control and experimental group, 16 each one. the study was finished at december 2011.

the objective of this work was to compare the effects of two balance training programs, one nintendo wii fit-based and the other traditionally-based without the use of a gaming system, on the balance, functionality and cognition of patients with parkinson´s disease. it was a prospective, single blinded, randomized clinical trial performed at brazil parkinson association and center of research of the courses of speech therapy, physical therapy and occupational therapy of são paulo university. 32 patients with parkinson´s disease on stages 1 and 2,5 of hoehn e yahr participated of this work. patients were randomized in control and experimental group, 16 each one. both groups performed 14 training sessions, twice a week, for seven weeks. each session was composed of a 30 minute-global-exercise series including stretching, muscle strengthen and axial mobility exercises. after this, both groups performed more 30 minutes of balance training: the control group performed balance exercises without external cues, visual or auditory feedbacks or cognitive stimulations; the experimental group performed the balance training with 10 wii fit games which stimulated motor and cognitive functions. the main outcome measures were: (1) unified parkinson´s disease rating scale (updrs); (2) berg balance scale (bbs); (3) unipedal stance test (ust) and (4) montreal cognitive assessment (moca). the statistical analysis was done by repeated measures anova in order to assess the possible differences among the analyzed variables. both groups showed improvement in the section ii of updrs, bbs, ust and moca. patients with parkinson´s disease showed balance and cognitive improvement with positive repercussion on daily living activities after 14 sessions of balance training without additional advantages to the virtual training.

Eligibility criteria:
inclusion criteria: * patients with parkinson´s disease * both gender * on stages 1 and 2,5 of hoehn e yahr exclusion criteria: * depression * cognitive impairment * deficits of visual acuity * score on berg balance scale under 46

Keywords: parkinson´s disease postural balance virtual reality
effect of thoracic manipulation on latent trigger point

Conditions: Trigger Points

Summary: the aim of this study is to investigate the effect of one session thoracic manipulation on pressure pain threshold and rhomboid muscle strength in healthy individuals with latent trigger point.

within the scope of the study, all individuals studying at sarayköy vocational school and volunteering to participate in the study will be screened.immediately after determining the latent trigger points in the rhomboid muscles, the participants will be randomized by computer method and divided into 2 groups. participants who underwent thrust thoracic manipulation will form the study group, and participants who received sham thrust thoracic manipulation will form the control group.pressure pain threshold will be evaluated with an algometer and rhomboid muscle strength will be evaluated with a hand dynamometer.

Eligibility criteria:
inclusion criteria: * not having any systemic disease * not having any neuromuscular deficit * to be defined as inactive (less than 30 minutes of moderate physical activity five times a week) according to the minimum activity guidelines published by the american college of sports medicine exclusion criteria: * being actively involved in any sport * participating in a regular exercise program

Keywords: latent trigger point thorasic manipulation muscle strength pressure pain threshold
epirubicin and thalidomide in treating patients with liver cancer

Conditions: Liver Cancer

Summary: rationale: drugs used in chemotherapy such as epirubicin use different ways to stop tumor cells from dividing so they stop growing or die. thalidomide may stop the growth of hepatocellular (liver) cancer by stopping blood flow to the tumor. combining epirubicin with thalidomide may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combining epirubicin with thalidomide in treating patients who have unresectable or metastatic liver cancer.

objectives: * determine the antitumor activity of epirubicin and thalidomide in patients with locally unresectable or metastatic hepatocellular carcinoma. * determine the toxic effects of this regimen in these patients. outline: patients receive epirubicin on days 1, 8, and 15 and thalidomide on days 1-21. courses repeat every 28 days. projected accrual: a total of 12 patients per year will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of hepatocellular carcinoma * locally unresectable or metastatic disease * measurable disease * no clinically apparent cns metastases * no carcinomatous meningitis patient characteristics: age * over 18 performance status * ecog 0-2 life expectancy * at least 12 weeks hematopoietic * absolute neutrophil count at least 1,500/mm\^3 * platelet count at least 75,000/mm\^3 hepatic * sgot no greater than 5 times upper limit of normal * bilirubin no greater than 3.0 mg/dl * inr no greater than 1.5\* * albumin at least 2.0 g/dl note: \*not required for patients receiving full anticoagulation with warfarin for deep vein thrombosis or pulmonary embolism renal * creatinine no greater than 2.0 mg/dl cardiovascular * no myocardial infarction within the past 6 months * lvef normal by echocardiogram or muga other * not pregnant or nursing * fertile patients must use effective contraception * willing and able to participate in the system for thalidomide education and prescribing safety (steps) program * no uncontrolled serious medical or psychiatric illness * no other concurrent uncontrolled malignancy prior concurrent therapy: biologic therapy * not specified chemotherapy * no more than 1 prior chemotherapy regimen for hepatocellular carcinoma * no prior chemoembolization to the liver endocrine therapy * not specified radiotherapy * not specified surgery * more than 2 weeks since prior major surgery

Keywords: adult primary hepatocellular carcinoma advanced adult primary liver cancer localized unresectable adult primary liver cancer recurrent adult primary liver cancer
feto-endoscopic tracheal occlusion (feto) for severe congenital diaphragmatic hernia

Conditions: Congenital Diaphragmatic Hernia; Pulmonary Hypoplasia; Pulmonary; Hypertension

Summary: tracheal occlusion ide approved by fda for congenital diaphragmatic hernia fetuses.

fetuses with congenital diaphragmatic hernia with liver-up, and an observed to expected lung-to-head ratio of \ 18 years old.... meet criteria to be offered fetal tracheal occlusion. we want to test feasibility and efficacy in our center.

Eligibility criteria:
inclusion criteria: * isolated cdh with liver up * severe pulmonary hypoplasia with ultrasound o/e lhr \<25% at the time of surgery * gestational age at feto procedure 27 weeks 0 days to 29 weeks 6 days * moderate pulmonary hypoplasia with ultrasound o/e lhr \<30% and liver-up at the time of surgery * gestational age at feto procedure 30 weeks 0 days to 31 weeks 6 days in this moderate category * maternal age greater than or equal to 18 years * gestational age at enrollment prior to 29 weeks 6 days, or 31 weeks 6 days in moderate category * normal karyotype or fish * normal fetal echocardiogram * singleton pregnancy * willing to remain in the greater cincinnati area for remainder of pregnancy * family considered and decline option of termination of the pregnancy at less than 24 weeks 0 days * family meets psychosocial criteria exclusion criteria: * patient \< 18 years old * multi-fetal pregnancy * rubber latex allergy * preterm labor, cervix shortened (\<15 mm) or uterine anomaly strongly predisposing to preterm labor, placenta previa * bilateral cdh, isolated left sided cdh with an o/e \> 30% * additional fetal anomaly by ultrasound, mri, or echocardiogram * chromosomal abnormalities * maternal contraindications to fetoscopic surgery or severe maternal condition in pregnancy * incompetent cervix with or without a cerclage * placental abnormalities known at time of enrollment * maternal hiv, hepatits b, hepatitis c * maternal uterine anomaly * no safe or technically feasible fetoscopic approach to balloon placement * participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy
the effects of pre-operative physical therapy education

Conditions: Breast Cancer

Summary: it is expected that patients who receive physical therapy before surgery will have greater range of motion (rom), strength, function, satisfaction, and less swelling, pain, and anxiety following surgery compared to those in the control group.


Eligibility criteria:
inclusion criteria: * be over the age of 18, * have a good understanding of the english language, and * be scheduled to undergo either a mastectomy, lumpectomy, alnd or sentinel lymph node dissection (slnd) with or without breast reconstruction. exclusion criteria: * if they previously underwent one of the previously mentioned procedures mastectomy, lumpectomy, alnd or sentinel lymph node dissection (slnd) with or without breast reconstruction.
the study of unasyn-s 12g/day for community acquired pneumonia (cap)

Conditions: Pneumonia, Bacterial

Summary: unasyn-s 12g/day (3 g four times a day) is the commonly used dosage depending on the severity for us, eu, china, taiwan and korea for over 20 years, however, unasyn-s 12g/day has not yet been approved in japan. the purpose of this trial is to evaluate the clinical efficacy and safety in japanese adult subjects with community acquired pneumonia receiving ampicillin sodium/sulbactam sodium, 12g/day (3 g four times a day ) iv.


Eligibility criteria:
inclusion criteria: * 16 years of age or older. * patients who were diagnosed as moderate to severe community acquired pneumonia requiring initial intravenous therapy and hospitalization. exclusion criteria: * known or suspected hypersensitivity or intolerance to ampicillin sodium/sulbactam sodium, other penicillins, or cephems. * hepatic dysfunction \[aspartate aminotransferase(ast), alanine aminotransferase (alt), total bilirubin \> 3 times upper limit of normal range values\]. * severe renal dysfunction (creatinine clearance \< 30 ml/min). * severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.

Keywords: ampicillin sodium/sulbactam sodium unasyn-s community acquired pneumonia bacterial pneumonia
hepatic encephalopathy prevention with polydextrose after tips: pilot study (poeme)

Conditions: Hepatic Encephalopathy

Summary: tips is a standard for the treatment of portal hypertension related complications. however, it remains at risk of he after tips (around 40% the first year). dysbiosis plays a key role in pathophysiology of he. polydextrose (pdx) is consider as a prebiotic. preliminary studies showed that pdx: 1. modified gut microbiota, enhancing "good bacteria" 2. improved gut permeability and immunity in 2 experimental models: infarction and colitis. the aim of this study is to assess pdx efficacy to prevent he during the first 6 months after tips in cirrhotic patients.

tips is a standard for the treatment of portal hypertension related complications. however, it remains at risk of he after tips (around 40% the first year). dysbiosis plays a key role in pathophysiology of he. polydextrose (pdx) is consider as a prebiotic. preliminary studies showed that pdx: 1. modified gut microbiota, enhancing "good bacteria" 2. improved gut permeability and immunity in 2 experimental models: infarction and colitis. patients will receive pdx 15 days prior to and 6 months after tips. we will assess the cumulative incidence of he 6 months after tips. patients will be followed-up for 12 months after tips.

Eligibility criteria:
inclusion criteria: * male or female at least 18 years of age * affected (c) cirrhosis in which the establishment of a tips is scheduled within the month for: the treatment of ascites or a refractory hydrothorax or the prevention of the recurrence of a related digestive hemorrhage portal hypertension * having signed the consent to participate in the study * women of childbearing age on effective contraception * affiliated to a social security scheme exclusion criteria: * contraindication for tips * digestive short circuit, chronic inflammatory bowel diseases * indications of tips in emergency or as part of the preparation for a surgical procedure, * liver transplant, * patient for whom the follow-up is considered impossible due to non-compliance with care or because the vital prognosis is estimated less than 6 months because of an incurable chronic pathology, * pregnant or lactating women, * those unable to receive enlightened information, * those participating in another interventional research including an exclusion period * persons placed under safeguard of justice, tutelage or curators.

Keywords: hepatic encephalopathy tips microbiota polydextrose
genetic determinants of the hypokalemic and hyperglycemic effect of albuterol inhalation

Conditions: Hyperkalemia; Chronic Renal Failure

Summary: several studies have indicated that albuterol administered either intravenously or by inhalation can significantly reduce plasma potassium concentration in patients suffering from chronic renal failure.in conjunction with the decrease in potassium concentration a modest rise in glucose concentration is usually noted. these metabolic effects are characterized by rapid onset occurring as early as 3-5 minutes following salbutamol administration and lasting for at least 1 hour. the role played by ß2ar polymorphisms in determining the bronchial and vascular response to ß2ar agonist drugs, have been confirmed by several studies. the purpose of the present study is to examine possible causal relationships between genetically based alteration in the structure of ß2ar and the metabolic effects of inhaled albuterol.


Eligibility criteria:
inclusion criteria: * patients regularly attending the nephrological clinic or the dialysis unit * persistent potassium concentration above 5 meq/l exclusion criteria: 1. patients suffering from active ischemic heart disease 2. patient with a recent history of arrhythmia 3. patients treated regularly with ß blockers 4. patients treated regularly with salbutamol or other ß2ar agonists 5. patients suffering from persistent tachycardia (pulse \> 100 beats/min) 6. patients who are hemodynamically unstable 7. patients suffering from any acute illness
a study evaluating the safety and clinical activity of hcv-796 in treatment-naive and non-responder subjects

Conditions: Hepatitis C

Summary: this is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of hcv-796 administered in combination with peginterferon alfa 2b (peg-intron) plus concomitant rebetol vs. peg-intron plus rebetol in hepatitis c virus (hcv) genotype 1-infected subjects who are either naive to treatment or who have previously failed treatment (non-responders).


Eligibility criteria:
inclusion criteria: * infection with hcv genotype 1. * hcv- infected subjects naive to treatment. * hcv-infected non-responder subjects. exclusion criteria: * women who are pregnant or breastfeeding. * alt \>/ or = 5x the upper limit of normal. * ast \>/ or = 5x the upper limit of normal.

Keywords: hepatitis c
a phase iii study of bd0801 combined with chemotherapy in recurrent, platinum-resistant epithelial ovarian cancer

Conditions: Ovarian Cancer

Summary: the standard systemic treatment for ovarian cancer is platinum-based chemotherapy. however, majority of patients relapse and eventually progress to platinum resistance. in patients with platinum-resistant or refractory ovarian cancer, effective treatment options are limited and the prognosis is very poor. angiogenesis is essential for tumor growth and metastasis, and vegf/vegf receptor(vegfr) signaling pathway is the most promising angiogenic target. this study aim to assess the efficacy and safety of the combination bd0801 and chemotherapy in patients with platinum-resistant recurrent ovarian cancer.


Eligibility criteria:
inclusion criteria: * female patients, \>/=18 years of age; * epithelial ovarian, fallopian tube or primary peritoneal cancer; * platinum-resistant disease (disease progression within \<6 months of platinum therapy) * eastern cooperative oncology group（ecog）performance status of 0-1 exclusion criteria: * non-epithelial tumours * ovarian tumours with low malignant potential * received 1 line of systemic therapy for ovarian cancer following platinum resistance and/or \> 1 line of non-platinum systemic therapy prior to platinum resistance. * prior radiotherapy to the pelvis or abdomen